FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 349:519-521 August 7, 2003 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Manson, J. E. Related Article by Hodis, H. N. PubMed Citation

During the past decade, postmenopausal hormone therapy became one of the most frequently prescribed therapies in the United States, with a highly diversified portfolio of presumed benefits for postmenopausal women. The belief that hormone therapy might reduce a woman's risk of coronary heart disease contributed considerably to its widespread use. Beginning in 1998, results from a series of randomized clinical trials, including new data presented in this issue of the Journal by Manson et al. (pages 523–534) and Hodis et al. (pages 535–545), have clearly demonstrated that hormone therapy does not slow the clinical or anatomical progression of established coronary . . . [Full Text of this Article]

Source Information

From the Departments of Internal Medicine/Cardiology (D.M.H.) and Pediatrics (T.D.H.), Wake Forest University School of Medicine, Winston-Salem, N.C.

Related Letters:

Hormone Therapy and Cardiovascular Disease
Kannel W. B., Levy D., Sullivan J. L., Bailar J. C. III
Extract | Full Text | PDF  
N Engl J Med 2003; 349:2075-2076, Nov 20, 2003. Correspondence

This article has been cited by other articles:

• Dunning, B. E., Gerich, J. E. (2007). The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications. Endocr. Rev. 28: 253-283 [Abstract] [Full Text]  
• Christian, R. C., Liu, P. Y., Harrington, S., Ruan, M., Miller, V. M., Fitzpatrick, L. A. (2006). Intimal Estrogen Receptor (ER){beta}, But Not ER{alpha} Expression, Is Correlated with Coronary Calcification and Atherosclerosis in Pre- and Postmenopausal Women. J. Clin. Endocrinol. Metab. 91: 2713-2720 [Abstract] [Full Text]  
• Iwakura, A., Shastry, S., Luedemann, C., Hamada, H., Kawamoto, A., Kishore, R., Zhu, Y., Qin, G., Silver, M., Thorne, T., Eaton, L., Masuda, H., Asahara, T., Losordo, D. W. (2006). Estradiol Enhances Recovery After Myocardial Infarction by Augmenting Incorporation of Bone Marrow-Derived Endothelial Progenitor Cells Into Sites of Ischemia-Induced Neovascularization via Endothelial Nitric Oxide Synthase-Mediated Activation of Matrix Metalloproteinase-9. Circulation 113: 1605-1614 [Abstract] [Full Text]  
• Genuis, S. J. (2005). The Proliferation of Clinical Practice Guidelines: Professional Development or Medicine-by-Numbers?. J Am Board Fam Med 18: 419-425 [Abstract] [Full Text]  
• Prentice, R. L., Langer, R., Stefanick, M. L., Howard, B. V., Pettinger, M., Anderson, G., Barad, D., Curb, J. D., Kotchen, J., Kuller, L., Limacher, M., Wactawski-Wende, J., for the Women's Health Initiative Investigators, (2005). Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial. Am J Epidemiol 162: 404-414 [Abstract] [Full Text]  
• Dietel, M., Lewis, M.A., Shapiro, S. (2005). Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20: 2052-2060 [Abstract] [Full Text]  
• Rzewuska-Lech, E., Jayachandran, M., Fitzpatrick, L. A., Miller, V. M. (2005). Differential effects of 17{beta}-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins. Am. J. Physiol. Endocrinol. Metab. 289: E105-E112 [Abstract] [Full Text]  
• Hosking, D.J., Geusens, P., Rizzoli, R. (2005). Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. QJM 98: 403-413 [Abstract] [Full Text]  
• Guzelian, P. S, Victoroff, M. S, Halmes, N C., James, R. C, Guzelian, C. P (2005). Evidence-based toxicology: a comprehensive framework for causation. Hum Exp Toxicol 24: 161-201 [Abstract]  
• Majumdar, S. R., Almasi, E. A., Stafford, R. S. (2004). Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women's Health Initiative. JAMA 292: 1983-1988 [Abstract] [Full Text]  
• Patten, R. D., Pourati, I., Aronovitz, M. J., Baur, J., Celestin, F., Chen, X., Michael, A., Haq, S., Nuedling, S., Grohe, C., Force, T., Mendelsohn, M. E., Karas, R. H. (2004). 17{beta}-Estradiol Reduces Cardiomyocyte Apoptosis In Vivo and In Vitro via Activation of Phospho-Inositide-3 Kinase/Akt Signaling. Circ. Res. 95: 692-699 [Abstract] [Full Text]  
• Kuller, L. H (2004). Commentary: Hazards of studying women: the oestrogen oestrogen/progesterone dilemma. Int J Epidemiol 33: 459-460 [Full Text]  
• Kannel, W. B., Levy, D., Sullivan, J. L., Bailar, J. C. III (2003). Hormone Therapy and Cardiovascular Disease. NEJM 349: 2075-2076 [Full Text]  
• Sabichi, A. L., Demierre, M.-F., Hawk, E. T., Lerman, C. E., Lippman, S. M. (2003). Frontiers in Cancer Prevention Research. Cancer Res. 63: 5649-5655 [Full Text]  
• SoRelle, R. (2003). Cardiovascular News. Circulation 108 : e9010-e9011 [Full Text]